Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897154 · ClinicalTrials.gov registry record
Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
A clinical trial, sponsored by Abbott Point of Care.
- Completed
- Registry status
- 297
- Enrollment target
NCT02897154: Completed study, sponsored by Abbott Point of Care.
NCT02897154 is a clinical trial that has completed, run by Abbott Point of Care. The registered enrollment target is 297 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02897154 has completed, sponsored by Abbott Point of Care.
- COMPLETED
- Registry status
- 297 participants
- Enrollment target
Study Summary
The objective of this study is to compare the performance of two i-STAT Analyzers in a Point-of-Care (POC) setting. The evaluation will be performed using a cartridge to test glucose, hematocrit and sodium on capillary specimens.
Primary Outcome
Data analysis
Interventions
- DIAGNOSTIC_TEST In-vitro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2016-05-10 |
| Est. Completion | 2017-03-15 |
What the finished NCT02897154 record still lists
NCT02897154 is an observational study that tracks outcomes without assigning an intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which In-vitro is the first listed.
NCT02897154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02897154 about?
NCT02897154 is a clinical study titled "Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples". The objective of this study is to compare the performance of two i-STAT Analyzers in a Point-of-Care (POC) setting. The evaluation will be performed using a cartridge to test glucose, hematocrit and sodium on capillary specimens.
What is the current status of trial NCT02897154?
This trial is currently completed. The enrollment target is 297 participants. The study started on 2016-05-10. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT02897154?
The interventions under investigation include: In-vitro (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02897154?
This trial is sponsored by Abbott Point of Care, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI